Everlywell AI Market Strategy Report - STD Tests

Answer Capsule

Everlywell is the most-mentioned brand in the STD Tests category but no longer the most recommended. In September 2026 the brand held a 74.84% raw mention presence rate, the highest of any tracked company, while its valid recommendation coverage fell to 20.70%, placing it second behind myLAB Box at 21.66%. The clearest win is sustained category-wide visibility and a rank-one rate of 5.73% that still ranks second in the category. The clearest weakness is a collapse in shortlist conversion: Everlywell lost 47 valid recommendations and 16 rank-one placements in a single month. The clearest opportunity is closing the gap between being named and being chosen, particularly on the surfaces where its presence is strongest.

Who This Report Is For

This report is written for Everlywell's growth, brand, and digital strategy leaders, and for category teams evaluating how AI-generated recommendations are reshaping shortlist formation in at-home and consumer-ordered STD testing.

Report Card

Executive Summary

Questions This Section Answers

• How does Everlywell's mention presence compare to its recommendation coverage?
• What happened to Everlywell's valid recommendation coverage between July and September 2026?
• Which platforms carry the strongest and weakest recommendation signal for Everlywell?

Everlywell enters September 2026 as the most visible brand in the STD Tests category and the second most recommended. The benchmark shows a raw mention presence rate of 74.84%, the highest of any tracked company, against valid recommendation coverage of 20.70%. That spread, roughly 54 percentage points between being mentioned and being shortlisted, is the defining feature of Everlywell's position this month.

The direction of travel is negative. Everlywell's valid recommendation coverage fell to 20.70% in September 2026 from 39.60% in July 2026, an 18.90 point decline that the benchmark classifies as beyond normal month-to-month variation. The single-month move was the largest in the category: coverage dropped 16.50 points from 37.20% in August 2026. The brand declined in each of the two months since the July baseline.

The recommendation count tells the same story in absolute terms. Everlywell held 65 valid recommendations in September 2026, down from 112 in August 2026, a loss of 47 qualified recommendations in one month. Rank-one placements were nearly halved, falling to 18 from 34, while the rank-one rate dropped to 5.73% from 15.40% at baseline.

The gap between presence and recommendation is the most important signal in this report. Everlywell's raw presence declined only modestly, from 81.20% in July 2026 to 74.84% in September 2026, a 6.36 point move. Its recommendation credit fell nearly three times as far over the same window. AI systems still surface Everlywell frequently; they are far less likely to name it as the top option or even a top-three option.

The strongest cluster is C01, Best STD Tests and Top STI Testing Services, which carries all 314 qualified observations in the September 2026 series. Everlywell's top-three rate within that cluster is 14.97% and its rank-one rate is 5.73%. The C02 comparison cluster and the C03 pricing cluster produced no qualified observations in any of the three months, so the public benchmark cannot yet show how Everlywell performs when buyers ask about alternatives or cost.

Platform behavior is uneven. Everlywell's strongest recommendation signal appears on AI Mode, where it holds a 20.48% valid recommendation coverage rate and 17 valid recommendations, and on AI Overviews at 25.37% coverage. Its weakest is Copilot, where coverage sits at 19.30% but rank-one rate falls to 1.75%, and Gemini, where presence is very high at 91.30% but recommendation coverage is only 11.59%. The pattern across platforms is consistent with the category-level finding: broad visibility, thinner conversion into first-position recommendations.

The clearest gap is competitive displacement at the top of the shortlist. myLAB Box now leads the category at 21.66% coverage and holds a rank-one rate of 8.92%, more than three points above Everlywell's. Everlywell still leads on presence, but presence is not the metric that determines whether a buyer sees the brand as the answer.

What Everlywell Is Winning

Questions This Section Answers

• What metrics is Everlywell still leading or nearly leading in the STD Tests category?
• How does Everlywell's rank-one rate compare to myLAB Box's?
• Which platforms produce the most recommendation credit for Everlywell?

Everlywell holds the highest raw mention presence rate in the category at 74.84%, ahead of LetsGetChecked at 66.24% and myLAB Box at 63.69%. When AI systems discuss STD testing options, Everlywell is the brand most likely to appear in the response at all.

The brand retains the second-highest valid recommendation coverage in the category at 20.70%, behind only myLAB Box at 21.66%. The gap between first and second is 0.96 points, narrow enough that the leadership position remains contestable.

Everlywell also holds the second-highest rank-one rate at 5.73%, with 18 first-position placements. Only myLAB Box places more often in the top slot, at 8.92% and 28 placements. This is a meaningful pocket of strength: even after a month of significant decline, Everlywell is still named first in a substantial share of recommendation-shaped answers.

On AI Overviews, Everlywell's valid recommendation coverage reaches 25.37%, the highest of any platform for the brand, with 17 valid recommendations. On AI Mode, coverage is 20.48% with 17 valid recommendations and a rank-one rate of 6.02%. These two surfaces carry the bulk of Everlywell's recommendation credit and represent the clearest evidence-backed wins in the dataset.

Sentiment framing is clean. Everlywell recorded 91 positive mentions, 144 neutral mentions, and zero negative mentions in September 2026, producing a net sentiment score of 0.3872. No tracked brand in the category recorded a negative mention, so this is a category-wide condition rather than a differentiated advantage, but it does mean Everlywell is not losing ground to cautionary or unfavorable framing.

Where Everlywell Has the Clearest AI Visibility Gaps

Questions This Section Answers

• Why does Everlywell's mention presence fail to convert into recommendation coverage?
• On which AI platforms is the gap between Everlywell's presence and rank-one placement widest?
• What happened to Everlywell's top-three inclusion rate compared to baseline?

The primary gap is recommendation conversion. Everlywell appears in 74.84% of qualified observations but is recommended in only 20.70%. That means roughly 54 percentage points of its presence does not convert into shortlist inclusion. myLAB Box, by comparison, converts 63.69% presence into 21.66% coverage, a materially tighter ratio.

The second gap is first-position strength. Everlywell's rank-one rate fell to 5.73% in September 2026 from 15.40% in July 2026, a 9.67 point decline. Its rank-one placement count fell to 18 from 34. myLAB Box now holds 28 rank-one placements against Everlywell's 18, despite Everlywell's substantially higher raw presence. The brand is being discussed more and chosen first less.

The third gap is top-three inclusion. Everlywell's top-three rate fell to 14.97% in September 2026 from 26.60% in July 2026, an 11.63 point decline. Its top-three count stands at 47, against myLAB Box's 52. The shortlist breadth that Everlywell held at baseline has narrowed.

Platform-level gaps sharpen the picture. On Gemini, Everlywell's raw mention presence rate is 91.30%, the highest of any platform-brand combination in the dataset, but its valid recommendation coverage is only 11.59% and its rank-one rate is 7.25%. The brand is nearly always present and rarely recommended. On Copilot, presence is 98.25% and coverage is 19.30%, but rank-one rate falls to 1.75%, with a single first-position placement. On ChatGPT, coverage is 42.86% with 9 valid recommendations, but rank-one rate is 4.76%, again showing presence without proportional first-position conversion.

The competitive displacement is concentrated. myLAB Box gained the category lead while Everlywell lost it, and the two brands now sit within one point of each other on coverage. The benchmark cannot attribute Everlywell's lost placements to a specific competitor at the prompt level, but the aggregate movement shows the leadership position changed hands in the same month Everlywell recorded its largest single-month decline.

Biggest Opportunity

Questions This Section Answers

• Which platforms offer the best opportunity to convert Everlywell's presence into first-position recommendations?
• Is Everlywell's problem fundamentally about visibility or about recommendation framing?

The clearest opportunity is converting Everlywell's category-leading presence into first-position recommendations on the surfaces where presence is highest and conversion is lowest. Gemini and Copilot are the sharpest examples: Everlywell appears in 91.30% and 98.25% of qualified observations on those platforms respectively, yet holds rank-one rates of 7.25% and 1.75%. The brand is already in the answer. The work is in the framing, structure, and supporting evidence that determine whether it is named first.

This is a recommendation-stage problem, not a visibility problem. The path forward runs through the owned answer layer and the citation architecture that AI systems draw on when they decide which brand to name first, not through additional presence-building.

Competitive Landscape

Questions This Section Answers

• How do Everlywell's recommendation metrics compare to myLAB Box, LetsGetChecked, and the rest of the field?
• What is Everlywell's average recommended rank against myLAB Box's?

myLAB Box holds the strongest recommendation-stage position in the STD Tests category in September 2026, with Everlywell a close second and LetsGetChecked third. The three brands are separated by 3.19 points of valid recommendation coverage, a narrower spread than the category showed in August 2026.

Average recommended rank covers rank-eligible recommendations only.

Everlywell sits second on top-three rate and second on rank-one rate, with an average recommended rank of 2.11 against myLAB Box's 1.95. The table shows a brand with strong shortlist presence and slightly weaker first-position strength than the category leader, and a clear separation from the rest of the field.

Prompt Evidence

AI Mode / Best STD Tests and Top STI Testing Services Prompt: "at home blood test" Result: Everlywell appeared in the response and received recommendation credit, contributing to its 20.48% coverage rate on this platform.

Gemini / Best STD Tests and Top STI Testing Services Prompt: "how to test for herpes" Result: Everlywell was present in 91.30% of Gemini observations but received valid recommendation credit in only 11.59%, illustrating the presence-to-recommendation gap on this surface.

Copilot / Best STD Tests and Top STI Testing Services Prompt: "Which online doctors are legit?" Result: Everlywell appeared in 98.25% of Copilot observations but held a rank-one rate of 1.75%, with a single first-position placement.

AI Overviews / Best STD Tests and Top STI Testing Services Prompt: "Where's the cheapest place to get blood work done?" Result: Everlywell received recommendation credit on AI Overviews, where its coverage rate of 25.37% is the highest of any platform for the brand.

What CiteWorks Studio Would Do Next

Phase 1: AI Market Discovery Audit Map the specific prompts, surfaces, and competitor placements behind Everlywell's 47-recommendation loss, with attention to Gemini and Copilot where presence is highest and rank-one conversion is weakest.

Phase 2: Recommendation Readiness Plan Prioritize the prompt patterns where Everlywell is present but not named first, and define the framing and evidence changes most likely to move it into the top slot.

Phase 3: Owned Answer Layer Buildout Strengthen the owned pages and structured content that AI systems retrieve when forming STD testing shortlists, with emphasis on the comparison and pricing questions the public benchmark cannot yet measure.

Phase 4: Citation and Authority Layer Development Develop the third-party and source-layer evidence that supports first-position recommendations, since source presence is part of the information environment AI systems draw on.

Phase 5: Monthly AI Visibility and Recommendation Tracking Track coverage, top-three rate, rank-one rate, and sentiment monthly against the LLM Authority Index baseline to confirm whether the decline has stabilized and whether rank-one strength recovers.

Why This Matters

Everlywell is winning the mention and losing the decision. In a category where buyers ask AI systems to name a testing provider, being discussed in 74.84% of answers while being recommended in 20.70% means the brand is frequently part of the conversation and frequently not part of the shortlist. The 47 recommendations lost in a single month represent buyers who asked a recommendation-shaped question and did not see Everlywell named as an option.

AI presence alone is not enough. The brands that convert presence into recommendation credit are the ones that appear in the owned answer layer and the citation layer AI systems synthesize from. For Everlywell, the next move is targeted correction of the prompt, page, and citation layers that determine first-position placement, starting with the surfaces where the brand is already visible and the conversion gap is widest.

Core Metrics

Sentiment Score

Sentiment Score = (positive mentions × 1 + neutral mentions × 0 + negative mentions × -1) / total mentions

For Everlywell in September 2026: (91 × 1 + 144 × 0 + 0 × -1) / 235 = 0.3872.

This matters because unclassified mention counts are misleading. A brand with 235 mentions and no sentiment breakdown looks identical whether those mentions are enthusiastic recommendations, neutral references in a list, or cautionary notes. Everlywell's 144 neutral mentions are the largest single block, meaning most of its presence is reference rather than endorsement.

Share of voice is a diagnostic metric, not a business KPI. A positive recommendation, a neutral reference, a cautionary mention, and a competitor-displaced mention are not equal in value, and counting all mentions as wins is bad measurement. Everlywell's 74.84% presence rate and its 20.70% recommendation coverage describe two different things, and only the second reflects whether the brand is being chosen.

Classified sentiment is required before interpreting AI visibility. Everlywell's zero negative mentions and 0.3872 net sentiment score indicate clean framing, but framing quality is not the same as recommendation strength. The brand is framed well and recommended less often than it was two months ago.

Sentiment by Platform

Questions This Section Answers

• On which platforms is Everlywell's sentiment driven by mostly neutral mentions rather than positive recommendations?
• Which platforms show sentiment scores that are positive but based on too few mentions to be reliable?

Methodology

1. This report is a benchmark-based analysis of Everlywell's position in the STD Tests category, drawing on the LLM Authority Index AI Market Discovery Index for September 2026 and the associated metrics aggregation. It is not a client engagement result.
2. The reporting window is September 2026, with July 2026 as the baseline month and August 2026 as the intervening measurement.
3. Six AI and search surfaces were tracked: ChatGPT, Copilot, Gemini, Perplexity, AI Overviews, and AI Mode.
4. Each monthly run began with 800 prompt-surface observations. September 2026 produced 611 unique questions, 440 relevant prompts, 360 irrelevant prompts, and 314 qualified benchmark observations.
5. The competitor universe contains 10 tracked brands: Everlywell, myLAB Box, LetsGetChecked, Nurx, Labcorp OnDemand, STDcheck.com, PlushCare, QuestDirect, Priority STD Testing, and Health Testing Centers.
6. Three buyer-intent clusters are defined: Best STD Tests and Top STI Testing Services (consideration), STD Test Comparisons and Service Alternatives (evaluation), and STD Test Pricing, Cost and Affordability (decision). Only the first cluster produced qualified observations in any of the three months.
7. Stage 0 extraction retains the query, surface, answer, brand outcome, recommendation placement, sentiment, and, where exposed, citations or attributable evidence sources.
8. A mention is counted when a tracked brand appears in a qualified observation in any context, regardless of whether it is recommended.
9. A valid recommendation is counted when a brand appears in a valid recommendation shortlist within a qualified observation. Negative, neutral, cautionary, comparison-anchor, and listed-only mentions are not counted as valid recommendations.
10. Brand-level percentages use the 314 qualified observations as the public denominator, not the 800 raw prompt-surface observations.
11. The August 2026 data contained recording errors for PlushCare and STDcheck.com that caused both brands to register 0.0% coverage that month. September movements for those two brands should be read against that data-quality issue.
12. The public benchmark does not measure market share, attributable sales, every possible AI response, organic-search ranking, social mention volume, private or sponsored channels, or causality from a metric movement alone. The benchmark identifies where attention is warranted; a company-level analysis is needed to explain why.

See Where AI Is Recommending Your Brand

The public benchmark shows where Everlywell stands in AI-generated STD testing recommendations. A company-level AI visibility audit maps the specific prompts, surfaces, competitors, and evidence sources behind those numbers, and turns the September 2026 decline into a prioritized plan for recovering first-position recommendation strength.